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ABSTRACT
Objectives. Rifampin is a potent inducer of the cytochrome P450 3A4 isoenzyme (CYP3A4) that metabolizes most
protease inhibitor (PI) antiretrovirals. This study was designed to evaluate the steady-state pharmacokinetics and
tolerability of the coadministration of the PIs saquinavir and ritonavir (a CYP3A4 inhibitor used as a pharmacoen-
hancer of other PIs) and rifampin when coadministered in healthy HIV-negative volunteers.
Methods. In an open-label, randomized, one sequence, two-period crossover study involving 28 healthy HIV-
negative volunteers, arm 1 was randomized to receive saquinavir/ritonavir 1000/100 mg twice daily while arm 2
received rifampin 600 mg once daily for 14 days. Both arms were then to receive concomitant saquinavir/ritonavir
and rifampin for 2 additional weeks. Vital signs, electrocardiography, laboratory analyses, and blood levels of total
saquinavir, ritonavir, rifampin, and desacetyl-rifampin, the primary metabolite of rifampin, were measured.
Results. In arm 1, 10/14 (71%) and, in arm 2, 11/14 (79%) participants completed the ﬁrst study phase; eight
participants in arm 1 and nine in arm 2 went on to receive both saquinavir/ritonavir and rifampin. Following
substantial elevations ( grade 2) in hepatic transaminases in participants receiving the coadministered agents, the
study was discontinued prematurely. Two participants in arm 1 displayed moderate elevations after ﬁve and four
doses of rifampin, respectively. In arm 2, all participants experienced severe elevations within 4 days of initiating
saquinavir/ritonavir. Clinical symptoms (e.g., nausea, vomiting, abdominal pain, and headache) were more common
and severe in arm 2. Clinical symptoms abated and transaminases normalized following drug discontinuation.
Limited pharmacokinetic data suggest a possible relationship between transaminase elevation and elevated rifampin
and desacetyl-rifampin concentrations.
Conclusions. Although not conﬁrmed in HIV-infected patients, the data indicate that rifampin should not be
coadministered with saquinavir/ritonavir.
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Introduction
T
uberculosis (TB) remains a major cause of
morbidity and death in the human immuno-
deﬁciency virus (HIV)-infected population, par-
ticularly in resource-limited areas [1]. New TB
infections progress rapidly to disease in the pres-
ence of HIV infection, and HIV is the risk factor
that has been most strongly correlated with the
reactivation of latent TB infection [2]. Concomi-
tant therapy of TB and HIV infection is compli-
cated. The rifamycin antibacterials, indicated for
multidrug treatment of active TB, also are potent
inducers of the cytochrome P450 3A4 isoenzyme
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(PI) antiretrovirals. There is a profound reduction
in PI exposure (80% to 90%) [3] when rifampin,
the most potent inducer of CYP3A4 among the
rifamycins, is coadministered with a PI.
The PI ritonavir is a powerful inhibitor of
CYP3A4. Its inhibitory effect on CYP3A4 has
led to its widespread adoption, at subtherapeutic
doses, as a pharmacoenhancer of other PIs. Data
from a small pharmacokinetic (PK) study indicated
that “boosting” doses of ritonavir could diminish
rifampin’s effect on CYP3A4 and increase
saquinavir blood levels to the therapeutic range
[4]. As a result, the US Centers for Disease
Control and Prevention (CDC) guidelines [5]
have suggested the concurrent administration
of saquinavir/ritonavir (400/400 mg twice daily),
together with nucleoside analogs, as a possible
HIV treatment regimen for use with a rifampin-
based TB treatment regimen.
In HIV-infected individuals not coinfected with
TB, the historical saquinavir/ritonavir 400/400 mg
twice-daily combination described in the CDC
guidelines [5] has been superseded by saquinavir/
ritonavir 1000/100 mg twice daily, a combination
that yields better saquinavir exposure and fewer
adverse events [6,7]. PK data also have conﬁrmed
thatthissmallerdoseofritonavirprovidesadequate
concentrations of saquinavir when coadministered
with rifampin [4]. Effective virological and immu-
nological responses subsequently were reported
from a small retrospective study of HIV/TB coin-
fected patients receiving both saquinavir/ritonavir
1000/100 mg twice daily and rifampin-based TB
treatment[8].Morerecently,aprospectivestudyof
once-daily HIV treatment using an investigational
saquinavir/ritonavir 1600/200 mg combination
alsoshowedadequatesaquinavirPKandconsistent
HIV treatment responses in a group of 32 patients
receiving rifampin [9]. In the context of regulatory
approval and the subsequent development of a
more convenient 500 mg ﬁlm-coated formulation
of saquinavir mesylate, the present prospective
study was undertaken to evaluate the steady-state
PK and tolerability of both saquinavir/ritonavir
1000/100 mg twice daily and rifampin when coad-
ministered in healthy HIV-negative volunteers.
Methods
This single-center, open-label, randomized, one-
sequence, two-arm crossover study was conducted
in compliance with the Declaration of Helsinki
(1996) and local Independent Ethics Committee
requirements (Comité Consultative de Protection
des Personnes dans la Recherche Biomédicale
d’Alsace No. 1, Strasbourg, France). Written
informed consent was obtained from all partici-
pants before any screening procedures were per-
formed. The study was conducted at the Institut de
Pharmacologie Clinique Roche in Strasbourg.
Twenty-eight healthy, nonsmoker, HIV-
negative volunteers were recruited. All partici-
pants (26 white, 1 black, 1 Indian) were males
ranging in age from 24 to 63 years. Mean body
weight was 80  11 kg. Participants were assessed
to be healthy on the basis of medical screening,
which included a physical examination, a medical
history, measurement of vital signs (including elec-
trocardiography [ECG]), and clinical laboratory
tests (e.g., hematology, blood chemistry, urinalysis,
and drug screening). Intake of inhibitors and
inducers of CYP3A4 within 4 weeks and of any
other medications within 2 weeks prior to the
administration of the ﬁrst dose of the study drugs
was prohibited. Consumption of grapefruit and
grapefruit juice was forbidden within 2 weeks prior
to study drug administration and through the end
of the study. During the study, no other medica-
tions were allowed with the exception of those to
treat adverse events.
Volunteers were randomized to receive either
saquinavir/ritonavir alone (arm 1) or rifampin
alone (arm 2) in phase 1 (days 1 to 14; Figure 1) of
the study in order to achieve steady-state levels.
Both study arms were then to receive saquinavir/
ritonavir and rifampin concomitantly on days 15
through 28 (phase 2). Two saquinavir 500 mg
tablets (saquinavir ﬁlm-coated tablet; Invirase
®;
Roche) and one ritonavir 100 mg capsule
(Norvir
®; Abbott Laboratories) were coadminis-
tered twice daily at 12-hour intervals in the
morning and evening following a standardized
meal to optimize absorption. Rifampin was admin-
istered as two 300 mg capsules (Rifadin
®; Sanoﬁ
Aventis) in the morning 30 minutes before break-
fast and 1 hour before saquinavir/ritonavir admin-
istration. Randomization numbers were generated
by Roche and provided to the study pharmacist,
who assigned them sequentially in the order in
which the volunteers were enrolled. Study drugs
were administered under staff supervision on days
when volunteers were required to return to the
clinical pharmacology unit. On other days, com-
pliance was assessed by daily phone calls and the
use of diary cards.
Blood levels of saquinavir, ritonavir, rifampin,
and desacetyl-rifampin—the active primary
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days 14 and 28. Each 5.5 mL blood sample was
collected in a lithium heparin-containing tube
from an indwelling catheter at:
• Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, and 24
hours after the administration of saquinavir/
ritonavir for the simultaneous saquinavir/
ritonavir assay
• Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and
24 hours after rifampin administration for the
rifampin/desacetyl-rifampin assay
Saquinavir and ritonavir were isolated from
plasma by liquid/liquid extraction, and plasma
concentrations were determined using a validated
speciﬁc liquid chromatography method with
tandem mass spectrometry detection. The limit of
quantiﬁcation was 1 ng/mL for both saquinavir
and ritonavir. Plasma concentrations of rifampin
and desacetyl-rifampin were determined by a vali-
dated liquid chromatography method with ultra-
violet detection. The limit of quantiﬁcation was
0.1 mg/mL for both rifampin and its metabolite.
Vital signs were taken and ECGs were per-
formed at several intervals before and after drug
administration. Clinical laboratory tests were
performed weekly and were analyzed by a local
analytical laboratory (Laboratoire Trensz, Stras-
bourg, France). All adverse events reported during
the study were recorded and graded as to intensity.
Pharmacokinetic parameters (Cmax [peak plasma
concentration], Tmax [time to Cmax], AUCt [area
under the concentration-time curve for the dosing
interval], and T1
2β [apparent elimination half-life])
of saquinavir, ritonavir, rifampin, and its main
metabolitewereestimatedfromtheconcentration-
time data using a noncompartmental method. No
formal conﬁrmatory hypothesis testing was
planned. P values were to be interpreted in an
exploratory manner. Safety data were evaluated
descriptively. Laboratory test values were graded
according to the AIDS Clinical Trial Group [10] or
the American Heart Association [11] systems as
appropriate or were compared with the normal
range supplied by the analyzing laboratory where
applicable.Theupperlimitsofnormal(ULN)were
41 IU/L for alanine aminotransferase (ALT) and
38 IU/L for aspartate aminotransferase (AST).
Results
A total of 10/14 (71%) participants in arm 1 and
11/14 (79%) in arm 2 completed the ﬁrst phase of
the study (i.e., received the ﬁrst 14 days of drug
treatment and completed a full steady-state PK
proﬁle; Table 1). All PK parameters (Table 2)
[12,13] were within expected ranges. On day 13,
two participants in arm 2 experienced grade 1
elevated transaminase levels.
Eight participants in arm 1 and nine in arm
2 went on to receive both saquinavir/ritonavir
and rifampin in the second phase of the study;
however, the study was discontinued prematurely
in all participants due to the occurrence of unex-
pected hepatic events. (Four participants from arm
1 and four from arm 2 had not received concomi-
tant saquinavir/ritonavir and rifampin [Table 1]).
Two of eight participants in arm 1 had displayed
moderate elevations in ALT of 5X and 8X ULN,
after ﬁve and four doses of rifampin, respectively,
at the time of study discontinuation (Figure 2).
The remaining six participants had received only
one or two doses of rifampin. Three of these par-
ticipants had normal transaminases at termination,
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Figure 1 Study design.
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Arch Drug Info 2009;2:8–16and three showed mild ALT elevations (grade 1
or less) of 1.05 to 1.8X ULN. In arm 2, all nine
participants experienced grade 4 ALT elevations of
between 11X and 70X ULN within 4 days of
initiating saquinavir/ritonavir (Figure 3a,b). The
transaminase elevations were noted after a single
dose of saquinavir/ritonavir in ﬁve of nine partici-
pants. Transaminase levels began to improve after
drug discontinuation.
Clinical symptoms included nausea, vomiting,
abdominal pain, and headache and were generally
more common and severe for participants in arm 2
(Table 3). One participant in arm 2, who had ex-
perienced a grade 1 ALT elevation while taking
rifampin alone during phase 1 of the study, was
hospitalizedfollowinga70XULNincreaseinALT
after three doses of saquinavir/ritonavir. Clinical
symptoms also abated following drug discontinua-
tion.TestresultsforhepatitisA,B,andC,cytomeg-
alovirus, Epstein-Barr virus, and varicella-zoster
virus were all negative after study termination.
Although the second (day 28) PK evaluation
was not performed, a few samples were available
from the 17 participants who had received com-
bined therapy during phase 2 of the study, and
these were analyzed for saquinavir, ritonavir,
rifampin, and desacetyl-rifampin concentrations
(Figure 4). Following the coadministration of
rifampin in arm 1, mean saquinavir and ritonavir
concentrations were found to be similar to those
observed in phase 1 of the study when these agents
were administered alone (data not shown). In arm
2, the addition of saquinavir/ritonavir therapy to
rifampin resulted in substantially lower saquina-
vir and ritonavir mean concentrations compared
with the mean concentrations of saquinavir and
ritonavir when administered alone in arm 1. This
was consistent with both the lack of steady-state
levels of saquinavir and ritonavir and the induction
of CYP3A4 by two weeks of rifampin.
Data on rifampin and desacetyl-rifampin con-
centrations available from four participants in arm
1 were used to characterize drug disposition, and
data from two additional participants were used to
characterize the absorption phase only (Figure 4a,
b). Of these six participants, ﬁve displayed
rifampin concentrations comparable with those
observed in arm 2 participants taking rifampin
alone (during the ﬁrst phase of the study) while the
remaining participant displayed an ~10-fold
higher rifampin concentration than the mean
during the ﬁrst phase of the study when rifampin
was administered alone (Figure 4a). This partici-
pant had not experienced elevated transaminases
at the time of study discontinuation. Desacetyl-
rifampin measurements were available from ﬁve
Table 1 Summary of reasons for and timing of participant withdrawal from the study
Reason for withdrawal
Arm 1 Arm 2
Days 1–14
Saquinavir/
Ritonavir
(N = 14)
Days 15–28
Saquinavir/
Ritonavir +
Rifampin
(N = 8)
Days 1–14
Rifampin
(N = 14)
Days 15–28
Rifampin +
Saquinavir/
Ritonavir
(N = 9)
Adverse event 1 1 — 6
Consent withdrawn 1 — 1 1
Premature study termination* 4
† 74
† 2
Total number discontinued 6 8 5 9
*At the time of study termination, these patients were still receiving trial treatment.
†Two participants discontinued prior to receiving 14 days of the study drug and two participants received the full 14 days and completed a full PK proﬁle.
Table 2 Steady-state pharmacokinetic parameters measured/estimated on day 14 of the study
N
Cmax
(mg/mL)
Tmax
(h)
AUCt
(mg·h/mL)
T1
2β
(h)
Saquinavir 10 4.54 4.00 29.1 5.55
(44.5) (3.00–6.00) (54.8) (18.3)
Ritonavir 10 1.72 4.00 10.5 4.32
(30.6) (2.00–5.00) (40.2) (29.5)
Rifampin 11 9.76 1.00 37.3 1.58
(40.0) (0.98–4.00) (23.0) (21.8)
Desacetyl-rifampin 11 0.807 2.00 4.21 2.15
(43.7) (1.00–4.00) (40.2) (30.0)
Median (min–max) for Tmax; geometric mean (CV%) for other parameters; t=12 hours for saquinavir/ritonavir and 24 hours for rifampin.
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Arch Drug Info 2009;2:8–16participants in arm 1, two of whom showed 4-fold
elevations in desacetyl-rifampin concentrations,
while one showed a 7-fold elevation relative to
those in arm 2 during the ﬁrst phase of the study
(Figure 4b).
In arm 2, a limited number of blood samples
obtained from six participants during the second
phase of the study provided rifampin and desa-
cetyl-rifampin-concentration data. Four partici-
pants showed no change in rifampin levels relative
to within-participant values receiving rifampin
alone, although three of these four participants
showed elevated desacetyl-rifampin (2- to 4-fold;
Figure 4b); the remaining two participants showed
elevated concentrations of both rifampin and
desacetyl-rifampin. Notably in arm 2, the three
participants who experienced the highest eleva-
tions in ALT (50X ULN) all showed elevated
rifampin and/or desacetyl-rifampin. Maximum
ALT increases in relation to rifampin and
desacetyl-rifampin concentrations during con-
comitant rifampin and saquinavir/ritonavir, as
determined by sparse sampling, are shown in
Table 4.
After the study had been terminated prema-
turely due to these hepatic toxicities, a 6-month
safety monitoring follow-up was implemented via
a protocol amendment for the 17 subjects who had
received triple therapy. The 6 months of additional
monitoring did not reveal any evidence for persis-
tent or new safety concerns and conﬁrmed that the
hepatotoxicity induced by the triple therapy had
resolved without sequelae for all participants.
Discussion
Coadministration of saquinavir/ritonavir 1000/
100 mg twice daily and rifampin 600 mg once
daily in healthy HIV-negative volunteers led to
rapid and signiﬁcant elevations in liver enzymes,
typically within 1 to 3 days. The effect was most
marked in those with steady-state rifampin con-
centrations at the time of saquinavir/ritonavir
initiation, and in these participants the limited PK
data suggested that the degree of transaminase
elevation was linked to increased concentrations
of rifampin and desacetyl-rifampin. The ﬁndings
are consistent with a hypothesis that saquinavir/
ritonavir inhibits normal metabolic breakdown of
rifampin and desacetyl-rifampin and that elevated
exposure exacerbates the hepatotoxic potential
of rifampin. Alternatively, the administration of
saquinavir/ritonavir in participants with highly
induced CYP3A4 (and perhaps of other isoforms)
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Figure 2 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels for two participants in study arm 1
who developed signiﬁcant (grades 2 and 3) elevations in ALT following concomitant dosing of rifampin (600 mg once daily)
with saquinavir/ritonavir (1000/100 mg twice daily). Participants took saquinavir/ritonavir alone for days 1 to 14. Falling levels
are postdiscontinuation. Numbers indicated are participant identiﬁers.
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Arch Drug Info 2009;2:8–16by rifampin could have led to the rapid generation
of toxic metabolite(s) of saquinavir and/or rito-
navir. However, additional data are needed to con-
ﬁrm or refute these possibilities. It should be noted
that the mechanisms underlying the hepatotoxicity
of rifampicin with saquinavir/ritonavir are unlikely
to be speciﬁc to the use of saquinavir; a recent trial
involving rifampicin with lopinavir/ritonavir also
had to be suspended because of elevated hepatic
transaminases [14].
On the basis of these ﬁndings, saquinavir/
ritonavir and rifampin should be considered con-
traindicated. A “Dear Healthcare Professional”
letter to this effect was issued by Roche, the manu-
facturer of saquinavir, in February 2005, and a
saquinavir label change acknowledged this conclu-
sion. Still, while the ﬁndings in healthy volunteers
are dramatic, hepatotoxicity of this extent and
magnitude has not been reported in clinical set-
tings where saquinavir/ritonavir and rifampin are
used together in HIV-positive populations [9,15].
This drug combination has not been uncommon
since the publication of the CDC guidelines for
the treatment of TB in the setting of TB in 2000,
and the ﬁndings reported here are puzzlingly dis-
cordant with reported data. In the prospective
TBQD study [9,15], rifampin therapy was initiated
2 months before the start of saquinavir/ritonavir
Figure 3 Alanine aminotransferase
(ALT) and aspartate aminotrans-
ferase (AST) elevations for all nine
participants in study arm 2 who
commenced rifampin (600 mg once
daily) + saquinavir/ritonavir (1000/
100 mg twice daily) after 14 days of
rifampin alone. Falling levels are post-
discontinuation. Numbers indicated
are participant identiﬁers. (a) ALT;
(b) AST.
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patients with HIV and TB and was continued for
7 months. Only two patients withdrew from
saquinavir/ritonavir therapy because of elevated
transaminases, and these elevations were only
5-fold above the ULN, substantially fewer patients
and lower elevations than were seen in the cur-
rent study in HIV-negative men who initiated
saquinavir/ritonavir after achieving steady-state
rifampin concentrations. Both patients with ele-
vated transaminases had concomitant chronic
hepatitis C virus (HCV) infection. Similarly, in a
retrospective study of saquinavir/ritonavir 1000/
100 mg in previously antiretroviral-naive patients
on rifampin-containing TB treatment, only one
patient out of 14 experienced a grade 3 transami-
nase elevation over 24 weeks and this patient was
also coinfected with HCV [8].
There is additional evidence that certain drug
toxicities can present differently in HIV-positive
vs. HIV-negative persons [16–22]. Rifamycin-
associated adverse events appear to occur less fre-
quently in the context of HIV infection [23–26].
In particular, a greater frequency of rifabutin-
associated neutropenia has been reported in HIV
seronegative individuals [23–25]. Of speciﬁc rel-
evance, the severe hepatotoxicity associated with
the use of a 2-month course of rifampin and
Table 3 Adverse events reported in >10% of participants
Body system/Adverse event
Arm 1 Arm 2
Total participants with at least
one adverse event
Saquinavir/
Ritonavir
(N = 14)
Saquinavir/
Ritonavir +
Rifampin
(N = 8)
Rifampin
(N = 14)
Rifampin +
Saquinavir/
Ritonavir
(N = 9)
Transaminase elevation — 2 — 9
Hepatomegaly — 2 — 5
Chromaturia — — 9 —
Gastrointestinal disorder
Nausea 4 — 1 8
Abdominal pain 2 1 1 4
Vomiting — — — 4
Flatulence 1 1 — 2
Nervous system disorders
Headache — — 2 —
Figure 4 Sparse concentration–time
points following initiation of the triple
combination in arm 1 () and in arm 2
( ) participants compared to the full
pharmacokinetic proﬁles obtained on
day 14 (arm 2; rifampin alone). (a)
rifampin; (b) desacetyl-rifampin.
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is uncommon in HIV-positive patients and no
higher in frequency than that seen for longer term
treatment with isoniazid [27–29]. By contrast,
studies in largely HIV-negative populations have
found a substantial increase in elevated transami-
nases for pyrazinamide therapy relative to iso-
niazid [30,31]. These rates are typically higher
than those observed in studies of pyrazinamide in
HIV-positive populations [29,32].
In conclusion, it is unclear why some adverse
effects of drug therapy, particularly hepatic
effects, appear at a higher rate in participants
without HIV infection. The available evidence
suggests that concomitant rifampin and sa-
quinavir/ritonavir may fall into this category of
different hepatotoxicity mechanisms between
populations. Given the importance of treating
TB in HIV infection and the disparity in the tox-
icity of combining rifampin with saquinavir/
ritonavir noted between this study and the
limited clinical data available, further research
may be warranted.
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Days on saquinavir/ritonavir and rifampin 4 2 2 2 1 1 1 1 1
†Abnormal at end of treatment with rifampin alone.
ND = Not determined (sample taken too late with a concentration below the limit of quantiﬁcation or no sample taken); ULN = Upper limit of normal; ↔ = no change.
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